EDAP TMS SA ADR
EDAP TMS SA ADR (FOCL) Expected Move
FOCL expected move through Oct 16, 2026 is 137.0%, with 25 days to expiration. The implied range is -$1.54 to $9.84, based on the previous trading day's options prices.
Read more
Tracking the FOCL expected move helps you see how far EDAP TMS SA ADR's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. EDAP TMS SA ADR's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the FOCL expected move for this week's options, in real time.
The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For FOCL, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The FOCL expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks EDAP TMS SA ADR is unlikely to go.
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications.
This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the FOCL expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The EDAP TMS SA ADR expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about FOCL.
FOCL Price
Drag chart to pan. Drag axes to zoom.
| Expiration | DTE | Expected move (USD) | Expected move (%) | Upper price | Lower price |
|---|---|---|---|---|---|
| Oct 16, 2026 | 25 | $5.69 | 137.0% | $9.84 | -$1.54 |
| Nov 20, 2026 | 60 | $2.09 | 50.3% | $6.24 | $2.06 |
| Dec 18, 2026 | 88 | $1.98 | 47.6% | $6.13 | $2.18 |
| Jan 15, 2027 | 116 | $1.63 | 39.2% | $5.78 | $2.53 |
As of September 18, 2026
Know What the Market Expects From FOCL
Track the FOCL expected move across every expiration, filter by IV rank and liquidity, and trade around the range the market is already pricing in.
Start your 14-day free trial→